[Efficacy of fluticasone propionate aerosol versus budesonide suspension in treatment of recurrent wheezing caused by bronchiolitis].
OBJECTIVE
To investigate the efficacy of fluticasone propionate aerosol (flixotide) versus budesonide suspension in the treatment of recurrent wheezing caused by bronchiolitis.


METHODS
A total of 214 infants with newly diagnosed bronchiolitis were randomly divided into flixotide treatment (106 infants) and budesonide treatment groups (108 infants), and were given aerosol inhalation of flixotide or budesonide for 3 months after achieving remission of clinical symptoms. Another 136 infants with bronchiolitis who did not receive regular inhalation of corticosteroid after achieving remission of clinical symptoms were enrolled as the control group. The follow-up visits were performed for 1 year, and the effects of the two therapeutic methods on recurrent wheezing were evaluated.


RESULTS
Compared with the control group, both the flixotide and budesonide treatment groups had significantly fewer times of wheezing episodes within 1 year and a significantly lower recurrence rate of wheezing within the first 3 months after regular inhalation of corticosteroid, but no significant differences were observed between the two treatment groups. The amount of corticosteroid inhaled and hospital costs in the budesonide treatment group were significantly higher than in the flixotide treatment group (P<0.01).


CONCLUSIONS
Continuous inhalation of flixotide or budesonide after remission of clinical symptoms in children with bronchiolitis can reduce wheezing episodes and the recurrence of wheezing, and flixotide treatment is superior to budesonide treatment in the aspects of hospital costs and the amount of corticosteroid used.
Department of Pediatrics, Provincial Hospital Affiliated to Medical University of Anhui, Hefei 230001, China. panjiahua1960@163.com.
Wei-Ping
WP
Lan
Jing
J
Wang
Chuan-Lin
CL
Dai
Jia-Hua
JH
Pan
D000336:Aerosols; D001988:Bronchiolitis / Q000150:complications*; D019819:Budesonide / Q000627:therapeutic use*; D005260:Female; D000068298:Fluticasone / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D008297:Male; D012008:Recurrence; D012135:Respiratory Sounds / Q000187:drug effects*; D013535:Suspensions
D000336:Aerosols; D013535:Suspensions; D019819:Budesonide; D000068298:Fluticasone